Medtech firm Samphire Neuroscience raised $2.3 million in Pre-Seed funding to introduce Nettle, a wearable neurostimulation device suitable for medical settings, improving menstrual health.
More than 90% of women who are of reproductive age will at some point in their lives experience mild to severe premenstrual symptoms, and up to 91% will experience dysmenorrhea, or cramping during the menstrual cycle.
Ten percent of people with vaginas worldwide suffer with endometriosis, while another five to eight percent have PMDD.
Medical personnel run the danger of underdiagnosing, gaslighting, or dismissing sufferers.
Better options are what Samphire Neuroscience thinks people with menstrual health issues should have.
The company, which was co-founded by lawyer Alex Cook and neuroscientist Emilė Radytė, both trained at Oxford and Harvard, is committed to providing safe, effective solutions that are especially customized to meet menstrual health needs without requiring significant compromises.
Nettle, their initial answer, is a wearable medical-grade neurostimulation device that is comparable to the one made by Flow Neuroscience. It was clinically demonstrated to be twice as effective in 2023 as the top 21 antidepressants.
The round also saw participation from prominent angel investors such as Dr Pamela Walker, founder of Thena Capital and Rowena Ironside, founder of Women on Boards UK.
